Sarepta Therapeutics Inc.
Rating
Updated: Aug 21, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene ther...
Latest News
7 days ago · marketbeat.com
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts NearSarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat.
8 days ago · seekingalpha.com
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
14 days ago · benzinga.com
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock LowerSarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
14 days ago · businesswire.com
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic YearCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne. Now in its ninth year, the program was created to recognize individuals living with Duchenne muscular dystrop.
17 days ago · prnewswire.com
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPTNEW YORK CITY and NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
18 days ago · zacks.com
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
1 month ago · defenseworld.net
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPTBank of America Corp DE increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 26.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,145,926 shares of the biotechnology company's stock after buying an additional 450,336 shares during the
2 months ago · zacks.com
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook UpdatedSRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
2 months ago · marketbeat.com
Sarepta Therapeutics Q2 Earnings Call HighlightsSarepta Therapeutics NASDAQ: SRPT reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing cash and investments by approximately $197 million during the quarter to $945 million.
2 months ago · seekingalpha.com
Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call TranscriptSarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove SRPT